A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity

References

• Belshe RB. The origins of pandemic influenza—lessons from the 1918 virus. N Engl J Med. 2005;353(21):2209–2211.
   PubMed Web of Science ®Google Scholar
• Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in guangdong, people's Republic of China, in February, 2003. Lancet. 2003;362(9393):1353–1358.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Wang X, Wen Y, Xie X, et al. Dysregulated hematopoiesis in bone marrow marks severe COVID-19. Cell Discov. 2021;7(1):60.
   PubMed Web of Science ®Google Scholar
• Wang X, Xu G, Liu X, et al. Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection. Cell Mol Immunol. 2021;18(10):2313–2324.
   PubMed Web of Science ®Google Scholar
• Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022;11(1):337–343.
   PubMed Web of Science ®Google Scholar
• Shen C, Zhang M, Chen Y, et al. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. Theranostics. 2019;9(1):210–231.
   PubMed Web of Science ®Google Scholar
• Shen C, Chen J, Li R, et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med. 2017;9(412):eaam5752.
   Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115–119.
   PubMed Web of Science ®Google Scholar
• Kim H, Webster RG, Webby RJ. Influenza virus: dealing with a drifting and shifting pathogen. Viral Immunol. 2018;31(2):174–183.
   PubMed Web of Science ®Google Scholar
• Kitler ME, Gavinio P, Lavanchy D. Influenza and the work of the World Health organization. Vaccine. 2002;20(Suppl 2):S5–14.
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clin Infect Dis. 2014;59(11):1519–1524.
   PubMed Web of Science ®Google Scholar
• Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–280.
   PubMed Web of Science ®Google Scholar
• Mlcochova P, Kemp SA, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599(7883):114–119.
   PubMed Web of Science ®Google Scholar
• Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2021;602:676–681.
   Web of Science ®Google Scholar
• Burki T. Outbreak of coronavirus disease 2019. Lancet Infect Dis. 2020;20(3):292–293.
   PubMed Web of Science ®Google Scholar
• WHO. Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. Geneva: World Health Organization; 2020.
   Google Scholar
• Baylor NW, Egan W, Richman P. Aluminum salts in vaccines–US perspective. Vaccine. 2002;20(Suppl 3):S18–S23.
   PubMed Web of Science ®Google Scholar
• Shi S, Zhu H, Xia X, et al. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37(24):3167–3178.
   PubMed Web of Science ®Google Scholar
• Wang B, Wang X, Wen Y, et al. Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response. Sci Rep. 2015;5(17695):17695.
   Google Scholar
• Huang FF, Barnes PF, Feng Y, et al. GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med. 2011;184(2):259–268.
   PubMed Web of Science ®Google Scholar
• Proud PC, Tsitoura D, Watson RJ, et al. Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. EBioMedicine. 2021;63:103153.
   PubMed Web of Science ®Google Scholar
• Saito H, Takenaka H, Yoshida S, et al. Prevention from naturally acquired viral respiratory infection by interferon nasal spray. Rhinology. 1985;23(4):291–295.
   PubMedGoogle Scholar
• Wu Y, Huang X, Yuan L, et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci Transl Med. 2021;13(606):eabg1143.
   PubMed Web of Science ®Google Scholar
• HogenEsch H, O'Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018;3:51.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Sitrin R. Surface phosphophilicity of aluminum-containing adjuvants probed by their efficiency for catalyzing the P–O bond cleavage with chromogenic and fluorogenic substrates. Anal Biochem. 2001;295(1):76–81.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li M, Yang F, et al. Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment. Hum Vaccin Immunother. 2015;11(5):1129–1139.
   PubMed Web of Science ®Google Scholar
• Miller MA, Stabenow JM, Parvathareddy J, et al. Visualization of murine intranasal dosing efficiency using luminescent Francisella tularensis: effect of instillation volume and form of anesthesia. PLoS One. 2012;7(2):e31359.
   PubMed Web of Science ®Google Scholar
• Southam DS, Dolovich M, O'Byrne PM, et al. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol. 2002;282(4):L833–L839.
   PubMed Web of Science ®Google Scholar
• Wang X, Li M, Lin Z, et al. Multifaceted characterization of recombinant protein-based vaccines: An immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine. Vaccine. 2018;36(50):7650–7658.
   PubMed Web of Science ®Google Scholar
• Yin X, Wang X, Zhang Z, et al. Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods. J Pharm Biomed Anal. 2020;177:112880.
   PubMed Web of Science ®Google Scholar
• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Pan BS, Perera SA, Piesvaux JA, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369(6506):eaba6098.
   Web of Science ®Google Scholar
• Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339(6121):786–791.
   PubMed Web of Science ®Google Scholar
• Wu J, Sun L, Chen X, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339(6121):826–830.
   PubMed Web of Science ®Google Scholar
• Sun X, Zhang Y, Li J, et al. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021;16(11):1260–1270.
   Web of Science ®Google Scholar
• Wang C, Guan Y, Lv M, et al. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and Is required for the host defense against DNA viruses. Immunity. 2018;48(4):675–687 e7.
   PubMed Web of Science ®Google Scholar
• Silvin A, Chapuis N, Dunsmore G, et al. Elevated calprotectin and abnormal Myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182(6):1401–1418 e18.
   PubMed Web of Science ®Google Scholar
• Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is marked by a Dysregulated Myeloid cell compartment. Cell. 2020;182(6):1419–1440 e23.
   PubMed Web of Science ®Google Scholar